产品
编 号：F082215
分子式：C17H20F2N4O3S
分子量：398.43
分子式：C17H20F2N4O3S
分子量：398.43
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
2mg
询价
询价
5mg
询价
询价
10mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 1226781-44-7
产品详情
生物活性：
Omarigliptin (MK-3102) is a potent, selective, orally active and cross the blood-brain barrier dipeptidyl peptidase 4 (DPP-4) inhibitor. Omarigliptin shows anti-parkinsonian activity. Omarigliptin has the neuroprotective effect to improve diabetes-associated cognitive dysfunction.
体内研究：
Omarigliptin (5 mg/kg; p.o.) enhances the intestinal glucagon like peptide-1 and crosses BBB in rats.Omarigliptin (2.5, 5 mg/kg; p.o.; once a week for 8 weeks) shows anti-diabetic activity in STZ-induced diabetic mice.Omarigliptin (5 mg/kg; p.o.; daily for 28 days) shows anti-parkinsonian activity in rats.Animal Model:12 weeks, C57BL/6 male mice
Dosage:2.5, 5 mg/kg
Administration:P.o.; once a week for 8 weeks (50 mg/kg streptozotocin (STZ); i.p.; daily for five days)
Result:Reduced the food and water intake, and caused a significant decrease in blood glucose, accompanied by increased serum insulin levels, improved insulin sensitivity and cognitive function, ameliorated diabetes-induced mitochondrial dysfunction in the brain.
Animal Model:250±35 g , rats
Dosage:5 mg/kg
Administration:P.o.; daily for 28 days
Result:Increased in brain GLP-1 concentration and passed through the BBB following oral administration.
Omarigliptin (MK-3102) is a potent, selective, orally active and cross the blood-brain barrier dipeptidyl peptidase 4 (DPP-4) inhibitor. Omarigliptin shows anti-parkinsonian activity. Omarigliptin has the neuroprotective effect to improve diabetes-associated cognitive dysfunction.
体内研究：
Omarigliptin (5 mg/kg; p.o.) enhances the intestinal glucagon like peptide-1 and crosses BBB in rats.Omarigliptin (2.5, 5 mg/kg; p.o.; once a week for 8 weeks) shows anti-diabetic activity in STZ-induced diabetic mice.Omarigliptin (5 mg/kg; p.o.; daily for 28 days) shows anti-parkinsonian activity in rats.Animal Model:12 weeks, C57BL/6 male mice
Dosage:2.5, 5 mg/kg
Administration:P.o.; once a week for 8 weeks (50 mg/kg streptozotocin (STZ); i.p.; daily for five days)
Result:Reduced the food and water intake, and caused a significant decrease in blood glucose, accompanied by increased serum insulin levels, improved insulin sensitivity and cognitive function, ameliorated diabetes-induced mitochondrial dysfunction in the brain.
Animal Model:250±35 g , rats
Dosage:5 mg/kg
Administration:P.o.; daily for 28 days
Result:Increased in brain GLP-1 concentration and passed through the BBB following oral administration.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备